SCHEMBL31078952

SCHEMBL31078952

O=C(NC(COCCCNC(=O)n1ccnc1)(COCCCNC(=O)n1ccnc1)COCCCNC(=O)n1ccnc1)OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.41
HRH4 Q9H3N8 1/20 0.39
POLB P06746 1/20 0.38
TGM2 P21980 1/20 0.38
ANPEP P15144 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KEAP1 Q14145 2/20 0.37
NFE2L2 Q16236 2/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MAPT P10636 2/20 0.36
GHSR Q92847 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980778 0.88 HTT (0.44) SMN1; SMN2LMNAHTTHRH4POLB
SCHEMBL30980576 0.81 LMNA (0.64) SMN1; SMN2LMNAHTTHRH4POLB
SCHEMBL3225482 0.78 SMN1; SMN2 (0.50) SMN1; SMN2LMNAHTTHRH4CYP19A1
SCHEMBL30980602 0.77 LMNA (0.48) SMN1; SMN2LMNAHTTHRH4TGM2
SCHEMBL12108559 0.77 MAPT (0.52) SMN1; SMN2LMNAHTTPOLBTGM2
SCHEMBL30980799 0.74 LMNA (0.49) SMN1; SMN2LMNAHTTCTSS
SCHEMBL19767522 0.74 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTPOLBTGM2
SCHEMBL31749309 0.74 LMNA (0.48) SMN1; SMN2LMNAHTTTGM2L3MBTL1
SCHEMBL7466451 0.74 HTT (0.61) SMN1; SMN2LMNAHTTHRH4POLB
SCHEMBL5859633 0.74 NAMPT (0.53) SMN1; SMN2POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651904-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
WO-2024155750-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed